Community-acquired pneumonia. Clinical recommendations. Yesterday, today and tomorrow. To the article (round-table discussion: physician, pulmonologist, clinical pharmacologist)

Cover Page

Cite item

Full Text

Abstract

Diagnostics and antimicrobial therapy of community-acquired pneumonia are discussed considering updated clinical recommendations. Diagnostic implications of clinical symptoms and radiologic investigation results are evaluated. Special attention is given to the choice of the first antimicrobial drug with regard to approximate etiological cause of pneumonia, disease severity, antibiotic resistance risk, and antimicrobial drug pharmacological properties. Evaluation of antimicrobial drug effectiveness and decision for future management tactics in case of its ineffectiveness as well as antimicrobial therapy duration are important practical aspects of patient management. Importance of present and future clinical recommendations for medical practitioners is emphasized.

About the authors

Leonid I. Dvoretsky

I.M.Sechenov First Moscow State Medical University (Sechenov University)

Email: dvoretski@mail.ru
D. Sci. (Med.), Full Prof. Moscow, Russia

Sergei V. Iakovlev

I.M.Sechenov First Moscow State Medical University (Sechenov University)

д-р мед. наук, проф. каф. госпитальной терапии №2; резидент Альянса клинических химиотерапевтов и микробиологов Moscow, Russia

Mariia A. Karnaushkina

I.M.Sechenov First Moscow State Medical University (Sechenov University)

Email: kar3745@yandex.ru
д-р мед. наук, проф. каф. госпитальной терапии №2 Moscow, Russia

References

  1. Welte T et al. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67 (1): 71-9.
  2. Fine M.J et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275 (2): 134-41.
  3. Taboada M et al. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother 2016; 71 (4): 862-70.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).